Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 4Myelodysplastic Syndromes 3Triple Negative Breast Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Lymphoma 2Leukemia 2Hematologic Neoplasms 2Colonic Neoplasms 2Cardiovascular Diseases 2Cardiotoxicity 2Carcinoma in Situ 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Nose Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 13Prednisone 10N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9Doxorubicin 9Vincristine 8Azacitidine 6romidepsin 5Gemcitabine 5Brentuximab Vedotin 5fludarabine 4Etoposide 4Dexamethasone 4pembrolizumab 3belinostat 3Lenalidomide 3Biopsy 310-propargyl-10-deazaaminopterin 3tazemetostat 2ruxolitinib 2ixazomib 2duvelisib 2Nivolumab 2Bendamustine Hydrochloride 2venetoclax 1tislelizumab 1thymoglobulin 1spartalizumab 1somatostatin, cyclic hexapeptide(Phe-Phe-Trp-Lys-Thr-Phe)- 1sodium-iodide symporter 1sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Peripheral × Electrocardiography × 1 year × Clear all
NCT04447027 2026-01-30

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 24 charts
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡